Royalty Pharma









		Press Releases \| Corporate Brochure
		2009 December 7, 2009 Royalty Pharma Announces that Alexander von Perfall, Joins Management Team 2008 July 8 , 2008 Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team April 23, 2008 RotaTeq - Royalty Pharma Purchase of RotaTeq Royalty From The Children's Hospital of Philadelphia 2007 December 18 , 2007 Lyrica - Royalty Pharma Purchase of Lyrica Royalty From Northwestern University May 4, 2007 Remicade - Royalty Pharma Purchase of Remicade Royalty From NYU 2006 October 26, 2006 Royalty Pharma Announces Agreement Regarding the Purchase of the rights to a preexisting Royalty Interest in Humira from AstraZeneca and CAT January 16, 2006 Emory Deal Turns Heads, Jumbo $525 million royalty rights payment captures Wall Street's Attention 2005 August 22, 2005 Royalty Pharma Acquires Memorial Sloan-Kettering Cancer Center's International Royalty Interest in Neupogen and Neulasta July 18, 2005 Gilead Sciences and Royalty Pharma Announce $525 Million Agreement with Emory University to Purchase Royalty Interest for Emtricitabine 2004 November 9, 2004 Ligand, Royalty Pharma Amend SERM Royalty Agreement January 22, 2004 Royalty Pharma acquires a portion of Memorial Sloan-Kettering Cancer Center’s U.S. Royalty Interest in Neupogen/Neulasta 2003 October 22, 2003 Ligand, Royalty Pharma Amend SERM Royalty Agreement July 30, 2003 Moody's rates Royalty Pharma Pharmaceutical Royalty Securitization AAA July 30, 2003 Standard & Poors - Royalty Pharma Finance Trust Rating AAA January 6, 2003 Ligand, Royalty Pharma Expand SERM Royalty Agreement, Form New Royalty Partnership for Targretin Capsules 2002 September 18, 2002 Ligand to Receive $3.5 Million as Royalty Pharma Exercises Another Option to Purchase Additional Rights to Future SERM Royalty Streams April 18, 2002 Ligand to Receive $3 Million as Royalty Pharma Exercises First Option to Purchase Additional Rights to Future SERM Royalty Streams March 6, 2003 Ligand, Royalty Pharma Conclude Agreement for Rights/Options Tied to Future SERM Royalty Streams 2001 August 8, 2001 EntreMed Sells Thalidomide Royalty Stream for $24.3 Million 1998 January 8, 1998 Xoma Receives $17 Million for anti-CD20 Antibody Patents and Related Rights and $10 Million from Genentech for 1998 hu1124 Program

	© Copyright 2005 Royalty Pharma. All Rights Reserved.